Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone furoate nasal spray clinical endpoint bioequivalence in seasonal allergic rhinitis
CTR20220428Phase 3Completed
- Sponsor
- Sichuan Puruite Pharmaceutical Technology
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mometasone in seasonal allergic rhinitis (SAR), sponsored by Sichuan Puruite Pharmaceutical Technology. Started Mar 2022; status: completed.
02
Drugs
mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20220428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220428.